Cordis set to blaze a trail in US drug-eluting stent market
This article was originally published in Clinica
The first FDA approval of a drug-eluting stent (DES) is on the horizon, with Cordis' (Johnson & Johnson) Cypher sirolimus-eluting stent expected to receive the nod from the agency within the next four months.
You may also be interested in...
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.